GSWM
TEVA icon

Golden State Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Golden State Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-500
Closed -$8.38K – 1696
2025
Q2 		$8.38K Sell
500
-100
-17% -$1.61K ﹤0.01% 1119
2025
Q1 		$9.22K Buy
+600
New +$10.7K ﹤0.01% 1014
2019
Q3 		– Sell
-23,000
Closed -$212K – 1143
2019
Q2 		$212K Hold
23,000
– – 0.07% 215
2019
Q1 		$361K Buy
+23,000
New +$406K 0.12% 147

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Golden State Wealth Management's TEVA Position: Q3 2025 in Review

Golden State Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 500 shares — an estimated $8.38K sold.

Golden State Wealth Management first reported a position in TEVA in Q1 2019 and held it in 4 quarters. The position peaked at $361K in Q1 2019. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Golden State Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Golden State Wealth Management sold 500 Teva Pharmaceuticals shares in Q3 2025, an estimated $8.38K.
  • Golden State Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 4 quarters.
  • Golden State Wealth Management's Teva Pharmaceuticals position peaked at $361K in Q1 2019.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Golden State Wealth Management's 13F filing for Q3 2025, filed 3 Nov 2025.